Development of novel targeted therapies and therapeutic vaccines for broad types of cancer
build significant value in our nanomaterial drug candidates that address unmet medical needs
We aspire to substantially improve health care using our nanotechnology platforms
PDX Pharmaceuticals started in 2010 as a spinoff from the Biomedical Engineering Department at OHSU. The company has developed novel cancer therapeutics by combining nanotechnology and cancer systems biology in collaboration with the Knight Cancer Institute of OHSU. PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE™) and is raising $5M to initiate the clinical trial in early 2022.
Nanoparticle platform for co-delivering siRNA, drugs, vaccines, and/or immunotherapies. This proprietary nanoparticle can load multiple cargo types at once and is capable of targeted delivery to solid tumors upon intravenous administration. Given intratumorally, it can deliver siRNA and adjuvant to both cancer and antigen presenting cells, leading to effective in situ tumor vaccination which generates antitumor immune effects to attack cancer anywhere in the body.
AIRISE™: Intratumoral cancer nano-immunotherapy that generates antitumor immune effects to attack metastatic tumors.
ARAC™: Systemic nano-immunotherapy counterpart of AIRISE™ for deeper tumors such as lung cancer. ARAC™ can render tumors sensitive to immune checkpoint inhibitors.
T-siHER2-NP™: nanoparticle based HER2-targeted therapy for HER2+ breast cancer
PDX Pharmaceuticals focuses on developing functionalized nanomaterials into drugs. We aspire to substantially improve health care using our nanotechnology platforms. PDX Pharma was established in 2010, supported by the Biomedical Engineering Department of Oregon Health and Science University (OHSU) School of Medicine and The Oregon Nanoscience and Microtechnologies Institute (ONAMI). We develop novel cancer therapeutics by combining nanotechnology and cancer systems biology. These proprietary therapeutics have been shown to overcome resistance of current targeted therapies and to also trigger antitumor immunity in animal models. Our nanoparticle platform can co-delivering siRNA, chemo drugs, vaccines, and/or immunotherapies and it is capable of targeted delivery of these cargos to solid tumors upon intravenous administration. These cargos are carefully selected based on strong scientific rationale and knowledge in precision medicine and patient care.
The Company’s strategy is to build significant value in our nanomaterial drug candidates that address unmet medical need and have substantial commercial potential, secure intellectual property rights, and initiate early stage commercial development. We are conducting IND enabling studies of our drug candidate (AIRISE™) and are raising $15M to initiate the clinical trial in early 2022.
Our technologies have been developed through support from NIH (NCI, NCATS, NIDDK, NIGMS, NIEHS, NIAID), ONAMI, OHSU, PNNL, and Foundations (Prospect Creek, Wayne D. Kuni & Joan E. Kuni, Gordon Moore, Hillcrest, Women’s Health Circle of Giving).